MYR Exit

MYR develops a novel, peptide-based, first-in-class drug (entry inhibitor) for the treatment of chronic hepatitis B and Delta infections. Clinical phase IIb currently in preparation.

Press releases


Most Successful Exit in the History of High-Tech Gründerfonds – Gilead Sciences to Acquire MYR GmbH One of the largest trade sales of a VC-financed German biotech start-up in the last 20 yearsMYR developed HepcludexTM (Bulevirtide), a first-in-class entry inhibitor…

MYR GmbH Announces 10 million $ Financing Round After Successful Clinical Phase 2a

Further product development to combat hepatitis delta virus infection received a boost today thanks to commitments from MYR GmbH investors Maxwell Biotech Venture Fund and High-Tech Gruenderfonds. The combined investment of 7.9 million Euro (approximately $10 million) will be used by MYR for further development of…

Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program

Co-Invests with Germany’s Public/Private High-Tech Gründerfonds, One of Europe’s Top Venture Funds Maxwell Biotech Venture Fund (MBVF), founded with the participation of the Russian Government’s Russian Venture Company, announced today its first investment involving the High-Tech Gründerfonds (HTGF), one of…

High-Tech Gründerfonds invests in a novel Hepatits B compound

German Biotech MYR GmbH develops the viral entry inhibitor Myrcludex, a so-called „first-in-class“ drug for the treatment of chronic hepatitis B and D infections. The HTGF investment of 500,000 € enables the start of Phase 1 of clinical development already in summer 2011. MYR develops its lead compound in close…

Info & Contact

Dimitry Popov


Eiermarkt 3c
30938 Burgwedel

In portfolio

21. Jan 2011 – 09. Dec 2020